Novel avenues to control blood pressure: targeting the renal lymphatic system.

Hypertension is associated with the activation of the immune and lymphatic systems as well as lymphangiogenesis. The changes in the lymphatic system are considered an adaptive response to mitigate the deleterious effects of immune and inflammatory cells on the cardiovascular system. In the article recently published in Clinical Science by Goodlett and collaborators, evidence is shown that inducing renal lymphangiogenesis after the establishment of hypertension in mice is an effective maneuver to reduce systemic arterial blood pressure.

Modulation of cardiac voltage-activated K currents by glypican 1 heparan sulfate proteoglycan.

Background: Glypican 1 (Gpc1) is a heparan sulfate proteoglycan attached to the cell membrane via a glycosylphosphatidylinositol anchor, where it holds glycosaminoglycans nearby. We have recently shown that Gpc1 knockout (Gpc1) mice feature decreased systemic blood pressure. To date, none has been reported regarding the role of Gpc1 on the electrical properties of the heart and specifically, in regard to a functional interaction between Gpc1 and voltage-gated K channels.

The role of the glypican and syndecan families of heparan sulfate proteoglycans in cardiovascular function and disease.

Heparan sulfate proteoglycans (HSPGs) are proteoglycans formed by a core protein to which one or multiple heparan sulfate chains are covalently bound. They are ubiquitously expressed in cellular surfaces and can be found in the extracellular matrix and secretory vesicles. The cellular effects of HSPGs comprehend multiple functionalities that include ) the interaction with other membrane surface proteins to act as a substrate for cellular migration, ) acting as a binding site for circulating molecules, ) to have a receptor role for proteases, ) to act as a coreceptor that can provide finetuning of growth factor receptor activity threshold, and ) to activate intracellular signaling pathways (Sarrazin S, Lamanna WC, Esko JD.

Influence of cardiopulmonary bypass on the plasma concentrations of atenolol.

Background: Betablockers are used in the treatment of angina pectoris and others ischemic coronary diseases, reducing mortality and cardiovascular events. Atenolol is a hydrophilic betablocker which is characterized by gastrointestinal absorption, small extent of distribution and renal function-dependent elimination.

Objective: The study objective was to determine the inter-individual variability of atenolol in coronary patients.